Discussions about new guidelines on molecular testing in patients with lung cancer and a keynote address from prominent researcher Tony S. Mok, MD, will be among the highlights of the upcoming 14th International Lung Cancer Congress.

The diagnosis of end-stage cancer rarely led to the clinically indicated discontinuation of statin therapy when prescribed for primary prevention.

Mutations of the HER2 gene in patients with non-small cell lung cancer, though rare, potentially could be treated with HER2-targeted drugs.

A new study has confirmed that low testosterone is a side effect in a large proportion of patients who received crizotinib for the treatment of ALK-positive non–small cell lung cancer.

Researchers are attempting to determine if targeting more than one tyrosine kinase provide a greater benefit in several clinical trials involving the investigational drug afatinib.